Saranac Lake, NY —Trudeau Institute will continue work to help its global partners develop vaccines and treatments for future COVID-19 variants, as well as prepare for outbreaks of other pandemics, through a grant funded by the F.M. Kirby Foundation.
The $45,000 grant has been awarded to Dr. William Reiley’s group to further characterize a recently identified mouse strain in his lab which is highly susceptible to SARS-CoV-2 infection. While existing mouse models have aided scientists in the development of vaccines and treatments against COVID-19, those models do not accurately depict acute life threatening COVID-19 disease as seen in humans, nor lasting effects seen in COVID-19 “long-haulers”.
“Our existing model is just too limited,” Dr. Reiley said. “Because of this, researchers have been hampered in their ability to understand the immune responses as they relate to control of virus replication, the viral dysregulation of the immune response, identify biomarkers of disease, and interrogate novel therapeutic targets.”